SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?


To: afrayem onigwecher who wrote (80595)9/30/2002 5:22:08 PM
From: StockDung  Respond to of 122087
 
GMXX By: nicotinepoison
30 Sep 2002, 02:59 PM EDT Msg. 2082 of 2103

And Alan- You might be interested in this!

Pumpers won't discuss this topic!

Now, think about this folks!

First, a quote from the interview with GRANT ATKINS!

Grant: Sure, I guess we’re just about through our reverse takeover and GeneMax Corp. will have approximately 15.3 million shares issued pursuant to the RTO of GeneMax Pharmaceuticals. Of that amount, all but approximately 265,000 shares are restricted under Rule 144 and/or voluntary pooling arrangements. The 265,000 trading shares represents the float, and I estimate that the float has been twice sold by naked shorting – in fact adding an artificial additional 265,000 failed delivery shares that have been purchased by investors. This means that there are twice as many investor shareholders in the company as there are trading shares in existence.

So EUDEVERSE REVERSE SPLIT left 750,000 shares! Now there are to be 15.3 million shares outstanding when the RTO is finished... Means the COMPANY HAS PRINTED 14.55 million shares and distributed to various creditors, INSIDERS, officers, directors, and GRANT ATKINS COMPANIES, and of course, "investors"!!!

It appears that the price "paid" by these above entities has been from about .15 to $2.00 per share, with the majority being $1 or below! Therefore, at 5.75 per share, most of the current stock represents about 69 MILLION DOLLARS IN PROFITS!

Now suppose some of the above stockholders decided that with only 265,000 "free trading" shares out, they could buy ALL THOSE SHARES FOR about 1.5 million dollars, and "trade amongst themselves the entire float, and keep the price up!

Seems like a good plan, to buy 1.5 million dollars worth of stock to protect 69 million dollars worth of profits, no?

But after they had "bought the float", guess what? There were still shares for sale! How could that be????

So that is when the lawsuits started flying...

Hey PUMPERS, how close am I?

Not accusing anyone of anything, just asking...

jmho

nic



To: afrayem onigwecher who wrote (80595)9/30/2002 5:25:19 PM
From: StockDung  Respond to of 122087
 
Winehouse's Alleged Scheme

tourolaw.edu

The complaint alleges that defendant Isaac Winehouse, doing business as Wall & Broad Equities, organized a "cartel" to purchase a percentage of the Nu-Tech convertible preferred in the names of nominees. He then allegedly arranged for a number of securities firms to become market makers in Nu-Tech common stock and proceeded to sell the common short, allegedly to drive the price of the common stock down.

The Dealings Among Nu-Tech, Winehouse and Plaintiff

Plaintiff Mordechai Gurary purchased 1,000 shares of Nu-Tech common on October 31, 1996 and another 5,500 shares on November 7, 1996 at $14.60 and $15.50 per share, respectively. In or about December 1996, the stock price began to decline. A concerned Gurary spoke to J. Marvin Feigenbaum, chairman of Nu-Tech. Feigenbaum told him that he had spoken to Winehouse and threatened that Nu-Tech would refuse to register the common stock into which the preferred was convertible unless Winehouse and his group stopped shorting the common. He predicted that this threat would convince Winehouse to stop shorting the stock because a refusal to register the common issued upon conversion would force Winehouse to cover his short position by purchasing Nu-Tech common in the open market, perhaps at higher prices. Gurary, evidently comforted, then purchased another 1,000 shares on December 24, 1996 at a price of $11.75 per share.

Gurary claims subsequently to have learned that Winehouse and his associates had continued to short the stock using nominee names, having arranged to "borrow" an unlimited number of shares for that purpose from market makers. On February 18, 1997, Gurary again spoke to Feigenbaum, who told him that he had met that day with Winehouse and others in another attempt to stop the short selling. Feigenbaum told Gurary that Nu-Tech had offered to repurchase the group's preferred shares at cost plus ten percent and to allow it to keep its existing profits from the short sales if the group would stop its activities but that Winehouse had refused. Feigenbaum, however, told Gurary that Nu-Tech would not give in to Winehouse and would refuse to register the short sellers' shares. Later that day, Gurary bought another 8,350 shares of Nu-Tech common at a price of $11.57.

On March 12, 1997, Feigenbaum and another Nu-Tech board member met again with Winehouse and asked that Winehouse and his group accept registration of the common stock into which their preferred was convertible over a period of twelve months rather than insisting that it be registered immediately. Winehouse again refused and said that he would continue to sell short.

Nu-Tech common stock dropped approximately $6 per share over the next two days. On March 14, 1997, the company issued a press release which stated that the price decline could be attributed to "possible sales by shareholders." No mention was made of the discussions between Nu-Tech and Winehouse, allegedly to avoid disrupting Nu-Tech's efforts to acquire Physicians Clinical Laboratory, Inc. ("PCL") out of bankruptcy.

A few days later, Gurary was approached through an intermediary and spoke with Winehouse, who allegedly admitted to him that he deliberately had shorted the stock to drive the price down, said that he intended to continue, and advised Gurary to sell his shares because the price would drop to "a dollar."



To: afrayem onigwecher who wrote (80595)9/30/2002 6:28:43 PM
From: StockDung  Respond to of 122087
 
`We Support Pigs': Grubman's E-mails on His Ratings (Update1)
By Phil Serafino and George Stein

New York, Sept. 30 (Bloomberg) -- Salomon Smith Barney Inc.'s former analyst Jack Grubman and his colleagues made clear in e- mails and memos that they didn't believe the ratings they assigned to companies such as Winstar Communications Inc., which were clients of the Citigroup Inc. investment banking unit, according to a lawsuit filed by New York Attorney General Eliot Spitzer.

Spitzer sued executives of telecommunications companies that awarded investment-banking business to Citigroup after they received sought-after shares in initial public offerings and their companies benefited from optimistic stock recommendations from Salomon Smith Barney. The suit didn't name Grubman as a defendant.

Grubman's lawyer Lee Richards said in a statement that Grubman ``had no responsibility for, nor did he influence, IPO allocations to telecommunications executives.''

``The suggestion in the complaint that Mr. Grubman's research was somehow altered to help enrich executives who received IPO allocations or to obtain their investment banking business is categorically false,'' Richards said.

The following are excerpts from some of the e-mails and memos. The brackets were added by Spitzer in the filing.

Sherlyn McMahon, a senior research associate under Grubman, sent him an e-mail relating a conversation with an institutional investor: ``She just thinks that we make ourselves look stupid by recommending names right up to the point of bankruptcy like WCII [Winstar], XOXO [XO Communications], MFNX [Metromedia Fiber]. She understands the banking relationship aspect.''

Later that afternoon, Grubman wrote an e-mail to Kevin McCaffrey, head of U.S. research:

``Most of our banking clients are going to zero and you know I wanted to downgrade them months ago but got huge pushback from banking. I wonder what use bankers are if all they can depend on to get business is analysts who recommend their banking clients.''

Salomon ranked stocks from 1 to 5, with one a ``buy,'' 2 an ``outperform,'' 3 a ``neutral,'' 4 an ``underperform'' and 5 a ``sell.'' Executives of Focal Communications Corp., a Salomon banking client, complained about some aspects of a Grubman report on Feb. 21, 2001, in which he rated the stock ``buy.'' Grubman said in an e-mail to two Salomon bankers:

``If I so much as hear as one more f---ing peep out of them, we will put the proper rating (ie. 4 not even 3) on this stock, which every single smart buysider feels is going to zero. We lost credibility on MCLD and XO because we support pigs like Focal.''

McMahon received an e-mail from a client that day asking, ``Focal and McLeod are pigs aren't they?'' McMahon responded, ``FCOM definitely MCLD hold not sell.'' Focal spokesman Andy Sachs declined to comment.

Spitzer said in his lawsuit that from 1998 through 2000, Salomon Smith Barney research analysts issued ``virtually no sell or underperform ratings for the more than 1,000 stocks they rated.''

John Hoffman, head of Salomon Smith Barney's head of global equity research management, wrote in a 2000 memo to Michael Carpenter, then chairman of Salomon Smith Barney, that there was ``legitimate concern about the objectivity of our analysts which we must allay in 2001.''

In a presentation at a Citigroup retreat in Armonk, New York, on stock recommendations as of Jan. 29, 2001, Carpenter said there were no ``sell'' and only one ``underperform'' ratings among the 1,179 companies covered by research.

``Ridiculous on face,'' Hoffman said in handwritten notes attached to the presentation.

Jeffrey Waters, associate director of U.S. equity research, told Salomon Smith Barney participants at a January 2000 ``Best Practices'' seminar:

``When you look at the market share gap between us and the three competitors who are trying to close, when I just eyeballed it, it looked to me like there is something like roughly a billion dollars of, maybe not equity capital markets but investment banking revenue, on the table for this firm.

``And that's a lot of money. And it's clear that research is driving a lot of this increasingly, and therefore as a [research] department, our goal has to be, to be a really effective partner in terms of helping drive initiation, execution and everything else, because there is a lot of money on the table for this company. And we'll all benefit from it.''

Salomon Smith Barney's ``research was basically worthless,'' Jay Mandelbaum, then global head of Salomon Smith Barney's retail stock-selling division, told Hoffman in February 2001. The lawsuit said that Mandelbaum threatened to terminate his unit's contribution to the research budget.

``There is a continuing shift in the rationalization that an analyst is the key element in banking success,'' Hoffman wrote in a 1998 presentation to key executives of Travelers Group Inc., then parent of Salomon Smith Barney.

Hoffman wrote Carpenter in December 2000 that one of his goals since becoming global director of research was ``to better integrate our research product with the business development plans of our constituencies, particularly investment banking.''

From 1999 through 2001, Salomon Smith Barney's U.S. research unit requested a year-end performance assessment from analysts and ``suggested'' they ``obtain collaborative feedback from their investment banking counterpart regarding establishing and modifying a list of coverage priorities.''

A technical analyst -- who rates stocks based on price chart and volume statistics rather than a company's business prospects - - downgraded Winstar on two occasions. When an institutional investor sent Grubman an e-mail asking that the analyst be punished, Grubman forwarded the message to his bosses, asking that something be done about the analyst. He expresses concern the analyst may also downgrade Level 3 Communications Inc., for which Salomon was marketing a stock sale.

``Here is yet another request that we should punish the technical analyst so that it does not impact us on Level 3,'' wrote Grubman. ``On the roadshow, I want to be able to say we are taking action on the technical analyst, otherwise investors will be afraid that the same thing will happen to Level 3.''

Grubman cited his contributions to investment banking in response to a request from equity research management, which was trying to determine his compensation for 2001.

``We were a lead manager in a $450 million overnight convertible offing of XOXO and a $750 million high yield offering for MCLD in January,'' Grubman wrote.

``We were a joint-lead manager for FON's (Sprint Corp.'s) secondary offering of $3 billion and we were a book-running manager of WCOM (WorldCom Inc.) $12 billion debt deal; in April/May. In addition, we were joint lead in a $300 million equity and $450 convertible offering for Citizens Communications, an S&P 500 company, on which we initiated coverage of June 20 following the offerings. We received the mandate for joint books on AT&T s current $5 billion debt offering.''

Grubman attached a four-page, single-spaced investment banking schedule to his memo, which, according to the lawsuit, listed the following business he had helped to bring in: 22 mergers and acquisitions; 15 equity offerings; 6 private equity transactions; 21 investment grade debt offerings; 12 bank loans; four derivative transactions; 15 high-yield offerings; and two other, unspecified transactions.



To: afrayem onigwecher who wrote (80595)9/30/2002 6:43:25 PM
From: StockDung  Read Replies (1) | Respond to of 122087
 
Waksal said to be near a plea deal Ex-ImClone chief reportedly may agree to jail time

By CBS.MarketWatch.com
Last Update: 6:03 PM ET Sept. 30, 2002

NEW YORK (CBS.MW) -- Former ImClone Systems CEO Samuel Waksal is close to reaching a plea-bargain agreement with prosecutors on numerous counts of securities fraud, according to news reports.
The New York Times and the Wall Street Journal, in separate reports, said that lawyers representing Waksal appear to be closing in on a deal under which the ex-biotech chief would plead guilty and agree to some jail time. In exchange, Waksal could reportedly get leniency for himself and family members.

Prosecutors have, according to news accounts, pressed for a sentence of as much as 10 years, but Waksal could end up spending less time behind bars under a plea agreement.

Fueling speculation that plea negotiations are in an advanced stage, Waksal's lawyers missed a deadline Friday for filing pretrial motions.

A spokesman for Waksal declined to comment.

Waksal was indicted last month on charges of insider trading, perjury, obstruction of justice and bank fraud. He has entered a plea of not guilty.

Waksal is accused of tipping off relatives that the Food and Drug Administration would reject ImClone's (IMCL: news, chart) application to market an anti-cancer drug, Erbitux, so that they could unload the company's stock before the news became public. Prosecutors haven't publicly identified the family members, but news accounts have said they are Waksal's father and one of his daughters, Aliza.

Prosecutors are also reportedly investigating a sale of nearly 4,000 shares of ImClone stock by Martha Stewart on the day before the FDA's rejection was announced.

The home-decorating expert, who is a friend of Waksal, has denied any wrongdoing and she hasn't been charged in the case. Still, the controversy has deflated the stock of her eponymous company, Martha Stewart Living Omnimedia (MSO: news, chart). Shares nudged down 1 cent to $7 Monday.

Shares of New York-based ImClone have also cratered from a high of more than $70 last December to less than $8 now.

ImClone's shares traded down 14 cents to $7.80.



To: afrayem onigwecher who wrote (80595)9/30/2002 8:30:06 PM
From: peter michaelson  Read Replies (4) | Respond to of 122087
 
Go Afreyem Onigwecher, Go!!! GMXX is a total success!



To: afrayem onigwecher who wrote (80595)10/1/2002 3:58:11 PM
From: StockDung  Read Replies (1) | Respond to of 122087
 
SEC ORDERS A SUSPENSION OF TRADING IN THE STOCK OF NATIONWIDE CAPITAL
CORPORATION

The Securities and Exchange Commission announced the temporary
suspension, pursuant to Section 12(k) of the Securities Exchange Act of
1934, of trading of the securities of Nationwide Capital Corporation
(stock symbol NCCN) of Houston, Texas, at 9:30 a.m. EDT on October 1,
2002, and terminating at 11:59 p.m. EDT on October 14, 2002.
The Commission temporarily suspended trading in the securities of
Nationwide Capital Corporation because of questions concerning the
accuracy of assertions by or about Nationwide on its Internet website,
marketing materials, company press releases and other publicly available
sources to investors concerning, among other things, (a) the company's
business operations, (b) the company's business relationships, (c) the
company's current financial condition, (d) the company's acquisition of
Your Corner Office (YCO), a privately held company, and (e) trading in
the company's common stock by related shareholders.

The Commission cautions broker-dealers, shareholders, and prospective
purchasers that they should carefully consider the foregoing information
along with all other currently available information and any information
subsequently issued by the company. Further, brokers and dealers should
be alert to the fact that, pursuant to Rule 15c2-11 under the Exchange
Act, at the termination of the trading suspension, no quotation may be
entered unless and until they have strictly complied with all of the
provisions of the rule. If any broker or dealer has any questions as to
whether or not it has complied with the rule, it should not enter any
quotation but immediately contact the staff of the Securities and
Exchange Commission in Washington, D.C. If any broker or dealer is
uncertain as to what is required by Rule 15c2-11, it should refrain from
entering quotations relating to National Capital Corporation securities
until such time as it has familiarized itself with the rule and is
certain that all of its provisions have been met. If any broker or
dealer enters any quotation that is in violation of the rule, the
Commission will consider the need for prompt enforcement action.

Any broker-dealer or other person with information relating to this
matter is invited to call Morgan Miller, Staff Attorney, in the
Washington, D.C. office of the Securities and Exchange Commission, at
(202) 942-4892. (Rel. 34-46575)